Jason A. Levy, Melissa Marchand, Leanne Iorio, Gilles Zribi, Michael P. Zahalsky. Effects of Stem Cell Treatment in Human Patients With Peyronie Disease. J Am Osteopath Assoc 2015;115(10):e8–e13. doi: 10.7556/jaoa.2015.124.
Download citation file:
Context: Peyronie disease (PD) is a connective tissue disorder involving the formation of fibrous plaques in the tunica albuginea. Abnormal plaques and scar tissue create a chronic state of inflammation, causing increased curvature of the penis as well as erectile dysfunction.
Objective: To determine the feasibility and effects of using placental matrix–derived mesenchymal stem cells (PM-MSCs) in the management of PD.
Methods: In a prospective study, patients with PD were injected with PM-MSCs, and followed up at 6-week, 3-month, and 6-month intervals to assess changes in plaque volume, penile curvature, and erectile function status (measured using peak systolic velocity, end-diastolic velocity, and the International Index of Erectile Function questionnaire).
Results: In the 5 patients enrolled in the study, statistically significant increases in peak systolic velocity occurred after PM-MSC injection (P<.01). Of a total of 10 plaques managed, 7 had disappeared completely at 3-month follow-up. Changes in end-diastolic velocity, stretched penile length, and penile girth were not statistically significant.
Conclusion: To our knowledge, this study is the first on the use of stem cells to manage PD in humans. The results suggest that PM-MSCs may be beneficial and effective as a nonsurgical treatment in patients with PD. Future studies with long-term follow-up in a larger sample of patients are warranted. (ClinicalTrials.gov number NCT02395029)
a For changes from baseline, positive percentages represent increases; negative percentages, decreases; 0, no change.
b After trimix injection.
c Patient 3 had no curvature.
Abbreviations: EDV, end-diastolic velocity; IIEF, International Index of Erectile Function (questionnaire); PSV, peak systolic velocity.
c Patients 1 and 2 refused reinjection with trimix at 3-month follow-up because they were satisfied with their results and did not want to undergo subsequent injection.
d Unable to calculate change.
e Patient 3 had no curvature.
This PDF is available to Subscribers Only
View Article Abstract & Purchase Options